10th Mar 2005 07:01
Oxford Biomedica PLC10 March 2005 FOR IMMEDIATE RELEASE 10 MARCH 2005 OXFORD BIOMEDICA TO PRESENT AT SG COWEN HEATH CARE CONFERENCE Oxford, UK - 10 March 2005: Oxford BioMedica (LSE:OXB.L), the leading genetherapy company, today announces that it will present at the SG Cowen HealthCare conference in Boston on Wednesday, 16 March, at 13:50 GMT (08:50 EST).Interested parties may access a live web cast of the presentation at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=OXB.L&item_id=1026109 It is recommended that listeners log on 15 minutes early in order to registerand download any necessary software. If you are unable to participate during thelive web cast, a recorded replay of the presentation will be available within 24hours of the completion of the presentation through 15 April 2005. -Ends- For further information, please contact: Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000Communications Scientific/Trade Press Enquiries:Sue Charles/ Katja Stout/ Ashley Lilly Tel: +44 (0)20 7886 8150Northbank Communications Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical development in 2005, and fourfurther preclinical candidates. The Company is underpinned by over 80 patentfamilies, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,Viragen, MolMed and Kiadis; and has licensed technology to a number of companiesincluding Merck & Co and Biogen Idec. Further information is available at www.oxfordbiomedica.co.uk. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica